ARTICLE | Company News
Management tracks: OncoMed, Neurocrine
January 9, 2018 11:21 PM UTC
Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on Sept. 19, 2017 and resumed chairman responsibilities on Dec. 4.
Neurology and endocrine company Neurocrine Biosciences Inc. (NASDAQ:NBIX) said CMO Christopher O’Brien will retire in February. He will be succeeded by Eiry Roberts. Roberts was VP of R&D at Eli Lilly and Co. (NYSE:LLY)...